In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Instrumental Improvement: Solexa Merges With Lynx

Executive Summary

Reverse merging into Lynx gives high-throughput sequencing play Solexa the instrument development capabilities, Nasdaq listing and US presence it lacked. What's more, combining Solexa's sequencing technology with the commercial infrastructure at Lynx was enough to secure top-notch management and cash to see the company through to its first product offering, expected as early as late 2005.

You may also be interested in...



The A-List: 2004's Trend-Shaping Series A Financings

Analyzing the venture financings closed by 2004's new crop of biotech, diagnostics, and medical device start-ups reveals today's trends that may shape tomorrow's health care industry. Here we point out eleven 2004 Series A financings that identify and illustrate what's hot.

The A-List: 2004's Trend-Shaping Series A Financings

Analyzing the venture financings closed by 2004's new crop of biotech, diagnostics, and medical device start-ups reveals today's trends that may shape tomorrow's health care industry. Here we point out eleven 2004 Series A financings that identify and illustrate what's hot.

US Genomics' New Resolution

In distancing itself from developing technology for single-molecule genome sequencing, US Genomics has partly moved from developing a potentially disruptive technology to providing incremental improvements, first in genomics research. The appeal is that the start-up can get to the market and generate product revenues faster. But whether its new focus will provide the big margins or access to big markets that venture investors find appealing remains an open question.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel